Zobrazeno 1 - 10
of 323
pro vyhledávání: ''
Autor:
Abhinav Zawar, Suresh Kumar Bondili, Manju Sengar, Lingaraj Nayak, Navin Khattry, Jayashree Thorat, Pradeep Ventrapati, Hashmukh Jain, Anant Gokarn, Sachin Punatar, Bhausaheb Bagal, Avinash Bonda
Publikováno v:
JCO Global Oncology
PURPOSE The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this retrospective analysis to study the pattern of
Autor:
Aleix Prat, Olga Martínez-Sáez
Publikováno v:
JCO Oncology Practice. 17:594-604
Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or amplified in approximately 20% of breast cancers, conferring an aggressive tumor behavior but also an opportunity for targeted therapies. In the advanced setting, the prognosis o
Autor:
Philip He, Robin Kate Kelley, Ho Yeong Lim, Takuji Okusaka, Thomas Yau, David Wai-Meng Tai, Ghassan K. Abou-Alfa, Masafumi Ikeda, Bruno Sangro, Yoon-Koo Kang, Silvia Damian, Johanna C. Bendell, Mitesh J. Borad, William P. Harris, Tae-You Kim, Shukui Qin, Alejandra Negro, Mallory Makowsky, Nathan Standifer, Masatoshi Kudo, Ann-Lii Cheng, Jordi Bruix, Antonio Gasbarrini, Wei Peng Yong
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 27
PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unre
Publikováno v:
JCO Oncology Practice. 17:e1235-e1245
PURPOSE: Temporary COVID-19 guideline recommendations have recently been issued to expand the use of colony-stimulating factors in patients with cancer with intermediate to high risk for febrile neutropenia (FN). We evaluated the cost-effectiveness o
Autor:
William C. Becker, Peter A. Glassman, Maria J. Silveira, Karl A. Lorenz, Maria A. Zenoni, Soraya Fereydooni, Karleen F. Giannitrapani, Amanda M. Midboe, Azin Azarfar
Publikováno v:
JCO Oncology Practice. 17:e1038-e1047
PURPOSE: To understand how patients and providers weigh the risks and benefits of long-term opioid therapy (LTOT) for cancer pain. METHODS: Researchers used VA approved audio-recording devices to record interviews. ATLAS t.i., a qualitative analysis
Autor:
Hiroji Iwata, Antonia Ridolfi, Christelle Levy, Yeon Hee Park, Ines Lorenzo, Fabrice Andre, Dejan Juric, Mario Campone, Tamar Safra, Hope S. Rugo, Norikazu Masuda, Frederic Forget, Juan Ignacio Delgado Mingorance, Ingrid A. Mayer, Sibylle Loibl, Pierfranco Conte, Jinhee Park, Eva Ciruelos, Xiaolei Zhou
Publikováno v:
Journal of Clinical Oncology. 39:2005-2015
PURPOSE In the phase III SOLAR-1 trial ( NCT02437318 ), the PI3Kα-selective inhibitor and degrader alpelisib significantly improved median progression-free survival when added to fulvestrant in patients with phosphatidylinositol-4,5-bisphosphate 3-k
Autor:
Mariana Chavez-MacGregor, Jiangong Niu, Xiudong Lei, Ning Zhang, Sharon H. Giordano, Zhigang Duan, Hui Zhao
Publikováno v:
JCO Oncol Pract
BACKGROUND: Tamoxifen and aromatase inhibitors (AIs) are used as adjuvant hormonal therapy (AHT) for early-stage hormone receptor–positive (HR+) breast cancer. Treatment for 5 years reduces cancer mortality by 30%. Despite this benefit, adherence t
Publikováno v:
JCO Oncol Pract
Cardiotoxicity is a well-established complication of multiple cancer therapeutics, and the one of the most prominent effects that limits the use of these agents is in the form of left ventricular dysfunction, otherwise known as chemotherapy-induced c
Autor:
Deogratias Ruhangaza, Alan Paciorek, Tharcisse Mpunga, Leslie Lehmann, Lawrence N. Shulman, Temidayo Fadelu, Paul H. Park, Jean Bosco Bigirimana, Yvan Butera, Caitlin Driscoll, Cyprien Shyirambere, Cam Nguyen, Aline Umwizerwa, Rebecca DeBoer, Clemence Muhayimana
Publikováno v:
JCO Global Oncology
PURPOSE Hodgkin lymphoma (HL) is highly curable in high-income countries (HICs), yet many patients around the world do not have access to therapy. In 2012, cancer care was established at a rural district hospital in Rwanda through international colla
Autor:
Junji Tsurutani, Caleb Lee, Ian E. Krop, Shunji Takahashi, Rashmi Krishna Murthy, Alvaro Moreno-Aspitia, Javad Shahidi, Masahiro Sugihara, Haeseong Park, Yasuaki Sagara, Kenji Tamura, Lin Zhang, Charles H. Redfern, Yoshihiko Fujisaki, Hiroji Iwata, Shanu Modi, Toshihiko Doi
Publikováno v:
Journal of Clinical Oncology. 38:1887-1896
PURPOSE Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a topoisomerase I inhibitor payload. A dose escalation and expansion phase I study evalua